1-855-378-42281-855-378-4228
One of the outpatient rehabilitation options for individuals in Moline Acres who are battling with opioid dependence and addiction is called opioid maintenance therapy. Licensed clinics and doctors are certified to administer certain medications to opioid dependent clients, many of which are opioids themselves and are addictive. With low enough doses however, the user does not experience high feelings but also doesn't have intense cravings and is not experiencing opioid withdrawal. Methadone is the first med administered for this purpose, but there are a few more choices to choose from.
Methadone is an opiate and is meant to be taken at an out-patient medical center certified to administer the med, that is taken daily in liquid or pill form. The cost of the drug is about one hundred and fifty dolloars a month. Buprenorphine is also an opioid based med, and is in pill form often taken one day on, one day off. But unlike Methadone which can only be dispensed in highly well-regulated medical centers, Buprenorphine can be prescribed and administered in doctor's offices. The cost monthly of buprenorphine is approximately $300.00 monthly for the generic version of the drug. There is also a type of buprenorphine containing the drug naloxone, which is a med that blocks the effects of opiates. An individual consuming this formulation, AKA Suboxone, would find it harder to get high from opioids if they relapsed while taking the drug. It is also taken on a daily basis, and costs about $450 /month. Naltrexone is an additional medication used in opioid maintenance therapy, but unlike the other drugs aforementioned it is an opiate blocker and is not an opioid. There is an option to take this medication as a monthly shot, which is called Vivitrol. As an opioid blocker, it prevents someone from getting high from opioids, and therefore lowers the risk associated with relapse. This daily shot costs anywhere from $1000 to $1200 a month.
For All Drug and Alcohol Rehab Programs In Moline Acres, Click Here.
